Following target identification and endotyping, we have the ability to design molecule compounds and progress these into clinical trials. In this final video, our team walks through our approach in this video to conclude the series from our SXSW keynote session.
Our team was able to identify lists of possible gene targets involved in disease by applying AI models on diverse sets of data such as scientific literature, patents, chemical databases, and patient data such as electronic health records or multi-omics datasets.
Following the generation of the list of targets, molecular design can start. Here we try to tackle an important aspect of making the drug brain penetrant. This is an important step where our team of scientists and machine learning researchers identify, design and test the best molecules.
The collaboration between our scientists and machine learning researchers gives us the ability to rethink and improve the process of drug discovery and development. Patients are at the heart of everything we do and this is reflected in our approach.
Back to blog post and videos
